Last edition
News about "Metabolic Dysfunction-Associated Steatohepatitis"
Tangram Therapeutics Advances TGM-312 into MASH Patient Cohorts in Phase 1/2 Trial
Tangram Therapeutics advances TGM-312 into MASH patient cohorts in its Phase 1/2 RESTORE-MASH trial while appointing Dr Sonya Montgomery as Chief Development Officer to drive its clinical pipeline.
Metabolic Dysfunction-Associated Steatohepatitis | 05/09/2026 | By News Bureau
GSK Receives Japan's First Approval for Bepirovirsen as Functional Cure for Chronic Hepatitis B
Japan’s MHLW approves Hibsago for eligible adults with chronic hepatitis B, following Phase 3 data showing a 19 percent functional cure rate after six months of treatment.
Metabolic Dysfunction-Associated Steatohepatitis | 25/08/2026 | By News Bureau | 127
Ribo and Madrigal Enter Global Licensing Deal for siRNA Programmes Targeting MASH
Suzhou Ribo Life Science and Madrigal Pharmaceuticals have signed a worldwide licensing agreement covering six pre-clinical siRNA programmes for metabolic dysfunction-associated steatohepatitis, with potential milestone payments of up to USD 4.4 billion.
Metabolic Dysfunction-Associated Steatohepatitis | 12/02/2026 | By News Bureau | 337
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy